Kymera Therapeutics (KYMR) Cash & Current Investments (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Cash & Current Investments data on file, last reported at $650.9 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 40.54% year-over-year to $650.9 million in Q1 2026; TTM through Mar 2026 was $650.9 million, a 40.54% increase from a year earlier, with the FY2025 full-year figure at $848.3 million, up 73.56% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $650.9 million, down from $848.3 million in the prior quarter.
• Over the last five years, Cash & Current Investments for KYMR reached as high as $848.3 million in Q4 2025 and fell as low as $33.7 million in Q1 2022.
• Historically, Cash & Current Investments has averaged $452.9 million across 5 years, with a median of $481.9 million in 2022.
• Across the five-year window, Cash & Current Investments plunged 89.89% in 2022 and soared 1076.52% in 2023, its largest moves.
• Year by year, Cash & Current Investments stood at $407.2 million in 2022, then declined by 7.93% to $374.9 million in 2023, then surged by 30.37% to $488.7 million in 2024, then soared by 73.56% to $848.3 million in 2025, then slipped by 23.26% to $650.9 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $650.9 million in Q1 2026, $848.3 million in Q4 2025, and $505.7 million in Q3 2025.